NASDAQ:TYME - Tyme Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.54 -0.08 (-4.94 %) (As of 04/18/2019 03:07 PM ET)Previous Close$1.62Today's Range$1.53 - $1.6152-Week Range$1.57 - $4.64Volume10,723 shsAverage Volume723,114 shsMarket Capitalization$159.85 millionP/E RatioN/ADividend YieldN/ABeta0.22 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Tyme Technologies, Inc., a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York. Receive TYME News and Ratings via Email Sign-up to receive the latest news and ratings for TYME and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TYME Previous Symbol CUSIPN/A CIK1537917 Webwww.tymetechnologiesinc.com Phone212-461-2315Debt Debt-to-Equity RatioN/A Current Ratio5.08 Quick Ratio5.08Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book5.70Profitability EPS (Most Recent Fiscal Year)($0.21) Net Income$-18,960,000.00 Net MarginsN/A Return on Equity-127.48% Return on Assets-109.15%Miscellaneous Employees11 Outstanding Shares103,796,000Market Cap$159.85 million Next Earnings Date6/12/2019 (Estimated) OptionableOptionable Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions What is Tyme Technologies' stock symbol? Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME." How were Tyme Technologies' earnings last quarter? Tyme Technologies Inc (NASDAQ:TYME) announced its quarterly earnings data on Monday, February, 11th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. View Tyme Technologies' Earnings History. When is Tyme Technologies' next earnings date? Tyme Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, June 12th 2019. View Earnings Estimates for Tyme Technologies. What price target have analysts set for TYME? 2 analysts have issued 1 year target prices for Tyme Technologies' shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Tyme Technologies' stock price to reach $10.00 in the next year. This suggests a possible upside of 549.4% from the stock's current price. View Analyst Price Targets for Tyme Technologies. What is the consensus analysts' recommendation for Tyme Technologies? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tyme Technologies. What are Wall Street analysts saying about Tyme Technologies stock? Here are some recent quotes from research analysts about Tyme Technologies stock: 1. According to Zacks Investment Research, "Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body's immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. " (4/17/2019) 2. HC Wainwright analysts commented, "We maintain our Buy rating of TYME and our 12-month price target of $9.50 per share. We derive our price target based on a net present value analysis of projected SM-88 revenues through FY2030 assuming a 12% discount rate and 2% terminal growth rate." (11/7/2018) 3. Canaccord Genuity analysts commented, "We continue to view SM-88’s ability to generate responses across ~15 solid and liquid tumor types and with durable effect in advanced cancer patients progressing on available therapies as intriguing and reiterate our BUY rating." (6/15/2018) Has Tyme Technologies been receiving favorable news coverage? Media coverage about TYME stock has been trending neutral recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tyme Technologies earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. Who are some of Tyme Technologies' key competitors? Some companies that are related to Tyme Technologies include Evolus (EOLS), G1 Therapeutics (GTHX), Eagle Pharmaceuticals (EGRX), Vectura Group (VEGPF), Odonate Therapeutics (ODT), Viking Therapeutics (VKTX), Lexicon Pharmaceuticals (LXRX), Vital Therapies (VTL), DiaMedica Therapeutics (DMCAF), Obseva (OBSV), Dermira (DERM), Forty Seven (FTSV), Revance Therapeutics (RVNC), Synthorx (THOR) and Kura Oncology (KURA). What other stocks do shareholders of Tyme Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Bausch Health Companies (BHC), OpGen (OPGN), Karyopharm Therapeutics (KPTI), Rigel Pharmaceuticals (RIGL), New Age Beverages (NBEV), NVIDIA (NVDA), Viking Therapeutics (VKTX), Verastem (VSTM), Allena Pharmaceuticals (ALNA) and Micron Technology (MU). Who are Tyme Technologies' key executives? Tyme Technologies' management team includes the folowing people: Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 56)Mr. Ben R. Taylor, Pres & CFO (Age 42)Mr. Michael S. Demurjian, Co-Founder, Exec. VP, COO & Director (Age 52)Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 55)Dr. Giuseppe Del Priore, Chief Medical Officer (Age 57) How do I buy shares of Tyme Technologies? Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Tyme Technologies' stock price today? One share of TYME stock can currently be purchased for approximately $1.54. How big of a company is Tyme Technologies? Tyme Technologies has a market capitalization of $159.85 million. The company earns $-18,960,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Tyme Technologies employs 11 workers across the globe. What is Tyme Technologies' official website? The official website for Tyme Technologies is http://www.tymetechnologiesinc.com. How can I contact Tyme Technologies? Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected] MarketBeat Community Rating for Tyme Technologies (NASDAQ TYME)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 120 (Vote Outperform)Underperform Votes: 133 (Vote Underperform)Total Votes: 253MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote "Outperform" if you believe TYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TYME will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/18/2019 by MarketBeat.com StaffFeatured Article: What is a Derivative?